Publications in the Year: 2023

Journal Article

Morad MA, Doudar NA, Tawfeek N, Yacoub M, Azoz T, Demerdash DE.  2023.  IL-4Rα (rs1801275) A>G polymorphism in Egyptian immune thrombocytopenia (ITP) patients: a single center experience. Hematology, Transfusion and Cell Therapy. xxx(2531-1379):1-8.
Hamed EM, Ibrahim ARN, Meabed MH, Khalaf AM, Demerdash DME, Elgendy MO, Saeed H, Salem HF, Rabea H.  2023.  The Outcomes and Adverse Drug Patterns of Immunomodulators and Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia Egyptian Patients with Hemorrhage Comorbidity. Pharmaceuticals . 16(1424-8247 ):868-884.
application/pdf iconpharmaceuticals-16-00868.pdf
Hamed EM, Ibrahim ARN, Meabed MH, Khalaf AM, Demerdash DME, Elgendy MO, Saeed H, Salem HF, Rabea H.  2023.  Therapeutic Outcomes of High Dose-Dexamethasone versus Prednisolone + Azathioprine, Rituximab, Eltrombopag, and Romiplostim Strategies in Persistent, Chronic, Refractory, and Relapsed Immune Thrombocytopenia Patients. Pharmaceuticals. 16(1424-8247 ):1215-1233.
application/pdf iconpaper_5.pdf
Demerdasha DE, Mohamadyb N, Abdelghany W, Youssef H.  2023.  Predictive factors of response to eltrombopag and romiplostim in Egyptian immune thrombocytopenia patients: a single center experience. Egyptian Journal of Haematology. 48(1110-1067):88-94.
application/pdf iconpaper_7.pdf
Hamed EM, Meabed MH, Ibrahim ARN, Khalaf AM, Demerdash DME, Elgendy MO, Saeed H, Mahmoud TM, Salem HF, Rabea H.  2023.  Clinical Care Team’s Guide for Awareness on Risk Assessment of Eltrombopag Complicating Acute Kidney Injury in Relapsed Immune Thrombocytopenic Patients: A Case Report. Medicina. 59(1648-9144):1645.
application/pdf iconmedicina-59-01645.pdf
Tourism